Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, Éric; Ledermann, Jonathan A.; Selle, Frédèric; Gebski, Val; Penson, Richard T.; Oza, Amit M.; Korach, Jacob; Huzarski, Tomasz; Poveda, Andrés; Pignata, Sandro; Friedländer, Michael; Colombo, Nicoletta; Harter, Philipp; Fujiwara, Keiichi; Ray‐Coquard, Isabelle; Banerjee, Susana; Liu, Joyce F.; Lowe, Elizabeth; Bloomfield, Ralph; Pautier, Patricia; Korach, Jacob; Huzarski, Tomasz; Byrski, Tomasz; Pautier, Patricia; Friedländer, Michael; Harter, Philipp; Colombo, Nicoletta; Pignata, Sandro; Scambia, Giovanni; Nicoletto, Maria Ornella; Nussey, Fiona; Clamp, Andrew R.; Penson, Richard T.; Oza, Amit M.; Velasco, A. Poveda; Rodrigues, Manuel; Lotz, Jean‐Pierre; Selle, Frédèric; Ray‐Coquard, Isabelle; Provencher, Diane; Aparicio, Aleix Prat; Boixader, Laura Vidal; Scott, Clare L.; Tamura, Kenji; Yunokawa, Mayu; Lisyanskaya, Alla; Médioni, Jacques; Pécuchet, Nicolas; Dubot, Coraline; Rouge, Thibault De La Motte; Kaminsky, Marie‐Christine; Weber, B.; Lortholary, Alain; Parkinson, Christine; Ledermann, Jonathan A.; Williams, Sarah; Banerjee, Susana; Cosin, Jonathan A.; Hoffman, James; Penson, Richard T.; Plante, Marie; Covens, Allan; Sonke, Gabe S.; Joly, Florence; Floquet, Anne; Banerjee, Susana; Hirte, Holger W.; Amit, Amnon; Park-Simon, Tjoung-Won; Matsumoto, Koji; Tjulandin, Sergei; Kim, Jae‐Hoon; Gladieff, Laurence; Sabbatini, Roberto; O’Malley, David M.; Timmins, Patrick; Kredentser, Daniel; Milagro, Nuria Laínez; Ginesta, M.P. Barretina; Martorell, Ariadna Tibau; Liaño, Alfonso Gómez de; González, Belén Ojeda; Mileshkin, Linda; Mandai, Masaki; Boere, Ingrid; Ottevanger, Petronella B.; Nam, Joo‐Hyun; Filho, Elias Abdo; Hamizi, Salima; Cognetti, Francesco; Warshal, David; Dickson-Michelson, Elizabeth; Kamelle, Scott; McKenzie, Nathalie D.; Rodriguez, Gustavo C.; Armstrong, Deborah K.; Chalas, Eva; Celano, Paul; Behbakht, Kian; Davidson, Susan A.; Welch, Stephen; Helpman, Limor; Fishman, Ami; Bruchim, Ilan; Sikorska, Magdalena; Słowińska, Anna; Rogowski, Wojciech; Bidziński, Mariusz; Śpiewankiewicz, Beata; Herraez, Antonio Casado; Fernández, César Mendiola; Gropp‐Meier, Martina; Saito, Toshiaki; Takehara, Kazuhiro; Enomoto, Takayuki; Watari, Hidemichi; Choi, Chel Hun; Kim, Byoung‐Gie; Kim, Jae‐Weon; Hegg, Roberto; Vergote, Ignace

doi:10.1016/s1470-2045(17)30469-2

articleThe Lancet OncologyJul 25, 2017Closed access

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

ÉPÉric Pujade-Lauraine JAJonathan A. Ledermann FSFrédèric Selle VGVal Gebski RTRichard T. Penson

Délégation Paris 5 · Université Paris Cité · +25 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,857

total citations

FWCI: 80.37
Percentile: 100%
References: 27

Citations per year

Authors

121

ÉP
Éric Pujade-LauraineCorresponding
Délégation Paris 5, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
JA
Jonathan A. Ledermann
University College London
FS
Frédèric Selle
Sorbonne Université, Hôpital Tenon
VG
Val Gebski
The University of Sydney
RT
Richard T. Penson
Massachusetts General Hospital

Topics & keywords

Topics

PARP inhibition in cancer therapy99%
Ovarian cancer diagnosis and treatment0%
Advanced Breast Cancer Therapies0%

Keywords

Olaparib
Medicine
BRCA mutation
Ovarian cancer
Internal medicine
Oncology
Placebo
PARP inhibitor

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.

Funding

ES
European Society for Medical Oncology